The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing

Pharmacogenomics

Volumn 13, Issue 11, 2012, Pages 1247-1256

  Chan, Sze Ling ^a   Suo, Chen ^b   Chia, Kee Seng ^a,b,c,d   Teo, Yik Ying ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b KAROLINSKA INSTITUTE   (Sweden)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

pharmacogenetic testing; pharmacogenomics; population attributable fraction; warfarin

Indexed keywords

WARFARIN;

ARTICLE; CHINESE; CYP2C9 GENE; DOSE CALCULATION; ETHNIC DIFFERENCE; GENE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; INTERNATIONAL NORMALIZED RATIO; JAPANESE; MAINTENANCE DRUG DOSE; NEGRO; PERSONALIZED MEDICINE; PHARMACOGENETICS; POPULATION GENETICS; RACE DIFFERENCE; SIMULATION; VKORC1 GENE; WARFARIN PHARMACOGENETIC TESTING;

AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETICS, POPULATION; GENOTYPE; HAPMAP PROJECT; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; WARFARIN;

EID: 84865518397     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.104     Document Type: Article

References (36)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl. 6), S160-S198 (2008).
2. Limdi NA, Arnett DK, Goldstein JA et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9(5), 511-526 (2008). (Pubitemid 351803913)
3. Takahashi H, Wilkinson GR, Nutescu EA et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16(2), 101-110 (2006). (Pubitemid 43145678)
4. Mushiroda T, Ohnishi Y, Saito S et al. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J. Hum. Genet. 51(3), 249-253 (2006).
5. Cho HJ, Sohn KH, Park HM et al. Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics 8(4), 329-337 (2007).
6. Tham LS, Goh BC, Nafziger A et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin. Pharmacol. Ther. 80(4), 346-355 (2006). (Pubitemid 44479750)
7. Ohno M, Yamamoto A, Ono A et al. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur. J. Clin. Pharmacol. 65(11), 1097-1103 (2009).
8. Lee M, Chen C, Chou C et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 10(12), 1905-1913 (2009).
9. Cooper GM, Johnson JA, Langaee TY et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112(4), 1022-1027 (2008).
10. Cavallari LH, Langaee TY, Momary KM et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87(4), 459-464 (2010).
11. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
12. Shaw PB, Donovan JL, Tran MT, Lemon SC, Burgwinkle P, Gore J. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. J. Thromb. Thrombolysis 30(2), 220-225 (2010).
13. Takeuchi F, Kashida M, Okazaki O et al. Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients. Circ. J. 74(5), 977-982 (2010).
14. Chan SL, Suo C, Lee SC, Goh BC, Chia KS, Teo YY. Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. Pharmacogenomics J. doi:10.1038/tpj.2011.7 (2011) (Epub ahead of print).
15. Duconge J, Cadilla C, Windemuth A et al. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in hispanics. Ethn. Dis. 19(4), 390-395 (2009).
16. Teo YY, Sim X, Ong RTH et al. Singapore genome variation project: a haplotype map of three Southeast Asian populations. Genome Res. 19(11), 2154-2162 (2009).
17. Schelleman H, Limdi NA, Kimmel SE. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics 9(9), 1331-1346 (2008).
18. Ross K, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra EJ. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J. Hum. Genet. 55(9), 582-589 (2010).
19. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 11(6), 781-791 (2010).
20. Yu HC, Chan TY, Critchley JA, Woo KS. Factors determining the maintenance dose of warfarin in Chinese patients. QJM 89(2), 127-135 (1996). (Pubitemid 26053126)
21. Blann A, Hewitt J, Siddiqui F, Bareford D. Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br. J. Haematol. 107(1), 207-209 (1999). (Pubitemid 29500828)
22. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am. J. Public Health 88(1), 15-19 (1998).
23. Marin-Leblanc M, Perreault S, Bahroun I et al. Validation of warfarin pharmacogenetic algorithms in clinical practice. Pharmacogenomics 13(1), 21-29 (2012).
24. Sagreiya H, Berube C, Wen A et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet. Genomics 20(7), 407-413 (2010).
25. Roper N, Storer B, Bona R, Fang M. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J. Mol. Diagn. 12(3), 283-291 (2010).
26. Shin J, Cao D. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics 12(1), 125-134 (2011).
27. Limdi N, Wadelius M, Cavallari L et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115(18), 3827-3834 (2010).
28. Kamali F, Wynne H. Pharmacogenetics of warfarin. Annu. Rev. Med. 61(1), 63-75 (2010).
29. Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am. J. Epidemiol. 99(5), 325-332 (1974).
30. Benichou J. Biostatistics and epidemiology: measuring the risk attributable to an environmental or genetic factor. C. R. Biol. 330(4), 281-298 (2007). (Pubitemid 46712173)
31. Limdi N, Goldstein J, Blaisdell J, Beasley T, Rivers C, Acton R. Influence of CYP2C9 genotype on warfarin dose among African American and European Americans. Personalized Med. 4(2), 157-169 (2007). (Pubitemid 46845895)
32. Scott S, Jaremko M, Lubitz S, Kornreich R, Halperin J, Desnick R. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics 10(8), 1243-1255 (2009).
33. Voora D, Koboldt D, King C et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87(4), 445-451 (2010).
34. Perera M, Gamazon E, Cavallari L et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin. Pharmacol. Ther. 89(3), 408-415 (2011).
35. Epstein R, Moyer T, Aubert R et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55(25), 2804-2812 (2010).
36. Stanek E, Sanders C, Hawk G et al. National benchmarking study of pharmacogenetic testing for warfarin. Clin. Pharmacol. Ther. 87(Suppl. 1), S44 (2010).